OREANDA-NEWS   Since March 2022, dental clinics have noted problems with the supply of ubistesin, an American drug for local anesthesia. Clinics also report the termination of the supply of Vitremer cement for the treatment of teeth in children and delays in the German ultracaine Sanofi Aventis. Difficulties are also observed with the purchase of dental equipment — hogs and cutters.

"Certain inconveniences are also associated with the lack of grinding wheels of the 3M company, which has left the Russian market. The domestic analogue is inferior to the imported material in quality. The abrasiveness of the discs is low, and for the primary grinding of the seal, not one disc is needed, but two or more, which increases the cost of treatment and increases its duration," Irina Lukashenok, a representative of the First Family Clinic of St. Petersburg, explained to RBC.

Due to the lack of ubistesin on the market, dentists began to use its domestic analogue - articaine—binergia. However, market participants note the lower effectiveness of the Russian drug: "In the case of ubistesin, only one capsule of the drug was needed to achieve the desired effect. Now we have to inject three or four capsules, which is a bit of an inconvenience for the patient and the doctor," said Louise Avtandilian, founder of the Smilestudio clinic.

Representatives of Russian clinics report that prices for drugs available for purchase have increased significantly, and their delivery time has increased two to three times. At the same time, there are no high-quality Russian analogues for most medicines.

According to the analytical company RNC Pharma, 93.9 thousand packages of ubistesin (369 million rubles, including VAT) were shipped to the Russian market in 2022. This is 70% less than in 2021 (-60% in ruble equivalent).